Litigation Details for Newron Pharmaceuticals S.p.A v. MSN Laboratories Private Limited (D. Del. 2021)
✉ Email this page to a colleague
Newron Pharmaceuticals S.p.A v. MSN Laboratories Private Limited (D. Del. 2021)
| Docket | ⤷ Try a Trial | Date Filed | 2021-06-10 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | Plaintiff | Referred To | |
| Parties | OPTIMUS PHARMA PVT LTD | ||
| Patents | 6,500,867; 8,076,515; 8,278,485; 8,283,380 | ||
| Attorneys | Bonnie Fletcher Price | ||
| Firms | Greenberg Traurig, LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Newron Pharmaceuticals S.p.A v. MSN Laboratories Private Limited
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial and ⤷ Try a Trial .
Details for Newron Pharmaceuticals S.p.A v. MSN Laboratories Private Limited (D. Del. 2021)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2021-06-10 | 1 | Exhibit 1-6 | . n1StS. 6,500,867 B1 12/2002 Virkki et al. 2002/00 19421…2001). of activity. See, e.g., U.S. Pat. No. 6,500,867, herein incor 10 … United States Patent (10) Patent No.: … appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below… United States Patent (10) Patent No.: | External link to document |
| 2022-05-13 | 120 | Claim Construction Chart | of U.S. Patent No. 8,076,515 (“the ’515 patent”), U.S. Patent No. 8,278,485 (“the ’485 patent”), and …and U.S. Patent No. 8,283,380 (“the ’380 patent”) for which the parties have a dispute, together with the… ’515 patent: 32-35, 40-44; ’485 record identified by patent, claim 37)…“stable dose of “a dose of ’380 patent at Abstract, 1:14- Not amenable to … proposal of this term being (’380 patent, claims nor decreased” 10:7-20, 11:9-65, | External link to document |
| 2022-10-05 | 180 | Amended Document - NOT Motion | of U.S. Patent No. 8,076,515 (“the ’515 patent”), U.S. Patent No. 8,278,485 (“the ’485 patent”), and …and U.S. Patent No. 8,283,380 (“the ’380 patent”) for which the parties continue have a dispute, together… ’515 patent: 32-35, 40-44; ’485 record identified by patent, claim 37)… to treat the selected CNS disorder” (’515 patent, claim 40) “classified as” … Plain and ordinary meaning.1 (’515 patent, claim 44) “are known to interact with” | External link to document |
| 2023-04-14 | 249 | Opinion - Memorandum Opinion | infringement of U.S. Patent No. 8,076,515 ("the '515 patent"), U.S. Patent No. 8,278,485 (&…the '485 patent"), and U.S. Patent No. 8,283,380 ("the '380 patent"). Before…quot;It is a bedrock principle of patent law that the claims of a patent define the invention to which…quot;A claim in a patent provides the metes and bounds of the right which the patent confers on the patentee…that inform patent law." Id. The ultimate question of the proper construction of a patent is a question | External link to document |
| 2023-05-01 | 254 | Notice of Service | Bihovsky, Ph.D. on Non-Infringement of U.S. Patent Nos. 8,076,515 and 8,278,485 by Prinston Pharmaceutical… 10 June 2021 1:21-cv-00843 835 Patent - Abbreviated New Drug Application(ANDA) Plaintiff | External link to document |
| 2023-05-31 | 259 | Notice of Service | Tagliati, M.D. Regarding Infringement of U.S. Patent No. 8,283,380 filed by MDD US Operations, LLC, Newron …Ph.D. Regarding Infringement of the '485 and '515 Patents by Prinston Pharmaceutical, Inc. and Reply Expert… 10 June 2021 1:21-cv-00843 835 Patent - Abbreviated New Drug Application(ANDA) Plaintiff | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
